Abstract 56P
Background
Hippocampus is associated with formation and storage of new memory and irradiation of same during whole brain radiotherapy in brain metastases leads to decline in the neurocognitive function. Recent advancements in radiation delivery in form of IMRT, Hippocampal avoidance has been made possible. We analyze feasibility of hippocampal sparing and associated neurocognitive and dosimetric assessment.
Methods
Between June 2016 to December 2017, 125 patients diagnosed radiologically and clinically with brain metastases were included in the study. Mini Mental State Examination (MMSE) and quality of life assessment with EORTC BN20 questionnaire were assessed along with dosimetry. Patients were assessed at baseline and followed by at 1, 3 and 6 months respectively. Factors were compared with the historical group with relation to quality of life especially neurocognitive functioning. Wilcoxon test for multiple comparisons was calculated to detect significant differences in global QoL scores.
Results
Median age of accrued 125 patients was 48 years. Median D100% and Dmax to contralateral hippocampus was 7.1Gy and 16.7Gy. With IMRT, the doses to other critical structures were reduced. Patients treated with IMRT were found to have achieved desired dose constraints to hippocampus. Assessment of neurocognitive function between two groups, there was no difference at 1 month after treatment, however, difference was seen at 3 and 6 months favouring hippocampal avoidance. No difference noted in other aspects of quality of life between two groups. No severe toxicities (Grade 3 and 4) were noted in either group. Median survival in the HA-WBRT arm was found to be 10.1 months.
Conclusions
Conformal avoidance of hippocampus during WBRT is associated with improved neurocognitive function and quality of life. IMRT has found to provide better dosimetric outcomes in HA-WBRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract